Published in Circ Res on March 24, 2014
Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma. Mol Cancer (2015) 1.51
Association of large intergenic noncoding RNA expression with disease activity and organ damage in systemic lupus erythematosus. Arthritis Res Ther (2015) 1.49
PANCR, the PITX2 Adjacent Noncoding RNA, Is Expressed in Human Left Atria and Regulates PITX2c Expression. Circ Arrhythm Electrophysiol (2016) 1.46
Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization. J Am Coll Cardiol (2015) 1.46
Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. Oncotarget (2015) 1.22
A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma. Cell Death Dis (2014) 1.22
Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proc Natl Acad Sci U S A (2014) 1.14
Noncoding RNA in age-related cardiovascular diseases. J Mol Cell Cardiol (2015) 1.04
Mechanisms of long noncoding RNA function in development and disease. Cell Mol Life Sci (2016) 1.04
Non-Coding RNAs Including miRNAs and lncRNAs in Cardiovascular Biology and Disease. Cells (2014) 0.94
Long noncoding RNAs in cardiac development and ageing. Nat Rev Cardiol (2015) 0.92
Long noncoding RNAs in diseases of aging. Biochim Biophys Acta (2015) 0.88
Long Non-Coding RNAs as Master Regulators in Cardiovascular Diseases. Int J Mol Sci (2015) 0.87
The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med (2015) 0.85
The emerging roles of long noncoding RNAs in common cardiovascular diseases. Hypertens Res (2015) 0.83
Heart Failure in Pediatric Patients With Congenital Heart Disease. Circ Res (2017) 0.81
Circulating Long Noncoding RNA UCA1 as a Novel Biomarker of Acute Myocardial Infarction. Biomed Res Int (2016) 0.81
The long noncoding RNA Chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat Med (2016) 0.80
An overview of long non-coding RNAs in ovarian cancers. Oncotarget (2016) 0.80
Comparison Analysis of Dysregulated LncRNA Profile in Mouse Plasma and Liver after Hepatic Ischemia/Reperfusion Injury. PLoS One (2015) 0.80
Long noncoding RNAs in kidney and cardiovascular diseases. Nat Rev Nephrol (2016) 0.79
Characters, functions and clinical perspectives of long non-coding RNAs. Mol Genet Genomics (2016) 0.79
LIPCAR: a mitochondrial lnc in the noncoding RNA chain? Circ Res (2014) 0.79
Assessment of Circulating LncRNAs Under Physiologic and Pathologic Conditions in Humans Reveals Potential Limitations as Biomarkers. Sci Rep (2016) 0.79
Genome-wide Long Non-coding RNA Analysis Identified Circulating LncRNAs as Novel Non-invasive Diagnostic Biomarkers for Gynecological Disease. Sci Rep (2016) 0.78
Dysregulated long intergenic non-coding RNA modules contribute to heart failure. Oncotarget (2016) 0.78
The Discovery of Novel Genomic, Transcriptomic, and Proteomic Biomarkers in Cardiovascular and Peripheral Vascular Disease: The State of the Art. Biomed Res Int (2016) 0.78
Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. Sci Rep (2016) 0.77
Heart failure: advanced development in genetics and epigenetics. Biomed Res Int (2015) 0.77
Non-coding RNAs in muscle differentiation and musculoskeletal disease. J Clin Invest (2016) 0.77
Long noncoding RNA variations in cardiometabolic diseases. J Hum Genet (2016) 0.77
Right ventricular long noncoding RNA expression in human heart failure. Pulm Circ (2015) 0.77
Epigenetics of the failing heart. Heart Fail Rev (2015) 0.77
A lncRNA Perspective into (Re)Building the Heart. Front Cell Dev Biol (2016) 0.77
Long non-coding RNAs link extracellular matrix gene expression to ischemic cardiomyopathy. Cardiovasc Res (2016) 0.76
LncRNApred: Classification of Long Non-Coding RNAs and Protein-Coding Transcripts by the Ensemble Algorithm with a New Hybrid Feature. PLoS One (2016) 0.76
Prospective and therapeutic screening value of non-coding RNA as biomarkers in cardiovascular disease. Ann Transl Med (2016) 0.76
Roles for long non-coding RNAs in physiology and disease. Pflugers Arch (2016) 0.76
Dawn of the Epi-LncRNAs: new path from Myheart. Circ Res (2015) 0.76
The long noncoding RNA Wisper controls cardiac fibrosis and remodeling. Sci Transl Med (2017) 0.76
The Long Noncoding RNA Landscape of the Ischemic Human Left Ventricle. Circ Cardiovasc Genet (2017) 0.75
Profiling analysis of long non-coding RNAs in early postnatal mouse hearts. Sci Rep (2017) 0.75
Non-coding RNAs: the dark side of nuclear-mitochondrial communication. EMBO J (2017) 0.75
Circulating "LncPPARδ" From Monocytes as a Novel Biomarker for Coronary Artery Diseases. Medicine (Baltimore) (2016) 0.75
Novel lincRNA SLINKY is a prognostic biomarker in kidney cancer. Oncotarget (2017) 0.75
Emerging roles for long noncoding RNAs in skeletal biology and disease. Connect Tissue Res (2016) 0.75
Long Noncoding RNA: Recent Updates in Atherosclerosis. Int J Biol Sci (2016) 0.75
Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Oncotarget (2016) 0.75
Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med (2016) 0.75
An evolutionary preserved intergenic spacer in gadiform mitogenomes generates a long noncoding RNA. BMC Evol Biol (2014) 0.75
Non-Coding RNAs in Lung Cancer: Contribution of Bioinformatics Analysis to the Development of Non-Invasive Diagnostic Tools. Genes (Basel) (2016) 0.75
Long non-coding RNAs in heart failure: a promising future with much to learn. Ann Transl Med (2016) 0.75
High Throughput Sequencing of Extracellular RNA from Human Plasma. PLoS One (2017) 0.75
Facts and updates about cardiovascular non-coding RNAs in heart failure. ESC Heart Fail (2015) 0.75
Differentially expressed circulating LncRNAs and mRNA identified by microarray analysis in obese patients. Sci Rep (2016) 0.75
Cardiac development: from current understanding to new regenerative concepts. J Thorac Dis (2017) 0.75
LncRNAs: From Basic Research to Medical Application. Int J Biol Sci (2017) 0.75
Identification of long non-coding RNAs GAS5, linc0597 and lnc-DC in plasma as novel biomarkers for systemic lupus erythematosus. Oncotarget (2017) 0.75
Circulating long non-coding RNAs NRON and MHRT as novel predictive biomarkers of heart failure. J Cell Mol Med (2017) 0.75
The circular RNA MICRA for risk stratification after myocardial infarction. Int J Cardiol Heart Vasc (2017) 0.75
Translational Perspective on Epigenetics in Cardiovascular Disease. J Am Coll Cardiol (2017) 0.75
The Management of Cardiovascular Risk through Epigenetic Biomarkers. Biomed Res Int (2017) 0.75
Increased plasma levels of lncRNA H19 and LIPCAR are associated with increased risk of coronary artery disease in a Chinese population. Sci Rep (2017) 0.75
miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nat Genet (2010) 4.06
Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum (2005) 3.44
Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation (2010) 2.99
Transforming growth factor-β-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol (2011) 2.35
Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2011) 2.27
MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology (2014) 2.23
Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation (2008) 2.18
Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery. Am J Cardiol (2009) 2.14
A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol (2011) 2.07
Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest (2014) 2.06
Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet (2010) 2.05
Regulation and function of miRNA-21 in health and disease. RNA Biol (2011) 1.99
MicroRNA-24 regulates vascularity after myocardial infarction. Circulation (2011) 1.98
Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J (2004) 1.98
Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res (2010) 1.96
Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol (2011) 1.94
Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol (2012) 1.93
The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun (2012) 1.88
Left ventricular remodeling after anterior wall acute myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] study group). Am J Cardiol (2006) 1.87
Implication of Ref-1 in the repression of renin gene transcription by intracellular calcium. J Hypertens (2003) 1.83
MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets (2010) 1.82
Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology (2012) 1.78
Usefulness of serial assessment of B-type natriuretic peptide, troponin I, and C-reactive protein to predict left ventricular remodeling after acute myocardial infarction (from the REVE-2 study). Am J Cardiol (2010) 1.78
Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation (2004) 1.67
Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol (2002) 1.66
Non-coding RNAs in cardiac remodeling and heart failure. Circ Res (2013) 1.66
MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nat Rev Nephrol (2011) 1.65
Functionality of two new polymorphisms in the human renin gene enhancer region. J Hypertens (2002) 1.65
High-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failure. Eur Heart J (2005) 1.64
Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Eur Radiol (2008) 1.63
Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J (2004) 1.59
Right ventricular systolic function in organic mitral regurgitation: impact of biventricular impairment. Circulation (2013) 1.58
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol (2008) 1.57
Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction. Circulation (2008) 1.56
Prognostic significance of circulating levels of angiogenic cytokines in patients with congestive heart failure. Am Heart J (2005) 1.53
Myocardial asynchronism is a determinant of changes in functional mitral regurgitation severity during dynamic exercise in patients with chronic heart failure due to severe left ventricular systolic dysfunction. Eur Heart J (2005) 1.52
The impact of the AMPD1 gene polymorphism on exercise capacity, other prognostic parameters, and survival in patients with stable congestive heart failure: a study in 686 consecutive patients. Am Heart J (2006) 1.48
Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv (2012) 1.47
Transcutaneous aortic valve implantation using the left carotid access: feasibility and early clinical outcomes. Ann Thorac Surg (2012) 1.47
MicroRNAs in the bile of patients with biliary strictures after liver transplantation. Liver Transpl (2014) 1.46
Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol (2008) 1.43
B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol (2004) 1.42
MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation (2013) 1.42
Aspirin does not adversely affect survival in patients with stable congestive heart failure treated with Angiotensin-converting enzyme inhibitors. Chest (2003) 1.42
Aortic valve implantation with the CoreValve ReValving System via left carotid artery access: first case report. J Thorac Cardiovasc Surg (2010) 1.41
Exosomes: new players in cell-cell communication. Int J Biochem Cell Biol (2012) 1.41
Association between the T-381C polymorphism of the brain natriuretic peptide gene and risk of type 2 diabetes in human populations. Hum Mol Genet (2007) 1.40
Prognostic value of procedure-related myocardial infarction according to the universal definition of myocardial infarction in saphenous vein graft interventions. Am Heart J (2009) 1.40
Exercise does not enhance the prognostic value of Doppler echocardiography in patients with left ventricular systolic dysfunction and functional mitral regurgitation at rest. Am Heart J (2008) 1.40
An unusual case of papillary fibroelastoma "invading" the mitral valve. J Thorac Cardiovasc Surg (2006) 1.38
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. Catheter Cardiovasc Interv (2009) 1.37
Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol (2002) 1.35
Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum (2011) 1.35
Hallmarks of ion channel gene expression in end-stage heart failure. FASEB J (2003) 1.27
Left ventricular abnormal response during dynamic exercise in patients with heart failure and preserved left ventricular ejection fraction at rest. J Card Fail (2008) 1.26
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis (2007) 1.24
MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail (2015) 1.24
Biogenesis and regulation of cardiovascular microRNAs. Circ Res (2011) 1.23
Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid Redox Signal (2010) 1.22
Circulating microRNAs as potential biomarkers of aerobic exercise capacity. Am J Physiol Heart Circ Physiol (2013) 1.20
The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum (2009) 1.18
Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford) (2009) 1.18
Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation (2013) 1.14
Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J (2010) 1.14
Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol (2003) 1.12
Two-dimensional maps and databases of the human macrophage proteome and secretome. Proteomics (2004) 1.11
Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol (2013) 1.11
Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest (2011) 1.10
Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J Pharmacol Exp Ther (2010) 1.08
Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am J Cardiol (2008) 1.07
Prevalence and determinants of cognitive impairment in chronic heart failure patients. Congest Heart Fail (2007) 1.07
Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation (2008) 1.07
Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J (2013) 1.06
A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J (2013) 1.06
Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol (2012) 1.06
MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age (Dordr) (2012) 1.06
Cardiovascular importance of the microRNA-23/27/24 family. Microcirculation (2012) 1.06
SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J (2012) 1.05
MicroRNAs in myocardial infarction. Arterioscler Thromb Vasc Biol (2013) 1.05